Challenges facing adjuvants for cancer immunotherapy

Immunology and Cell Biology

Volumn 82, Issue 6, 2004, Pages 644-650

  Mesa, Circe ^a   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Immune adjuvant; Impaired dendritic cell; Tumour immunotherapy

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; HEAT SHOCK PROTEIN; IMMUNOLOGICAL ADJUVANT; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONTANIDE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OIL; OLIGODEOXYNUCLEOTIDE; PHOSPHORYL LIPID A; QS 21; SQUALENE; UNCLASSIFIED DRUG; VASCULOTROPIN; VERY SMALL SIZE PROTEOLIPOSOME; WATER;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CROSS PRESENTATION; CYTOKINE RELEASE; DENDRITIC CELL; EMULSION; GENE EXPRESSION; HUMAN; IMMUNE DEFICIENCY; IMMUNOPOTENTIATION; IMMUNOREACTIVITY; NONHUMAN; POLARIZATION; REGULATORY T LYMPHOCYTE; REVIEW; SAFETY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR EDITING; TUMOR ESCAPE; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

MYCOBACTERIUM BOVIS BCG;

EID: 9444228872     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0818-9641.2004.01279.x     Document Type: Review

References (80)

1. Manickasingham SP, Reis a Sousa C. Mature T cell seeks antigen for meaningful relationship in lymph node. Immunology 2001; 102: 381-6.
2. Janeway CA Jr. The targeting of effector molecules in the immune system. Bioessays 1986; 5: 216-20.
3. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 2001; 13: 114-19.
4. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of blader cancer: 20 years on. Lancet 1999; 353: 1689-94.
5. Duda RB, Yang H, Dooley DD, Abu-Jawdeh G. Recombinant BCG therapy suppresses melanoma tumour growth. Ann. Surg. Oncol. 1995; 6: 542-9.
6. Brunner C, Seiderer J, Schlamp A et al. Enhanced dendritic cell maturation by TNF-a or Cytidine-Phosphate-Guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol. 2000; 165: 6278-86.
7. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol. 1998; 161: 3042-9.
8. Martin-Orozco E, Kobayashi H, Van Uden J, Nguyen M-D, Kornbluth RS, Raz E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int. Immunol. 1999; 11: 1111-18.
9. Tsuji S, Matsumoto M, Takeuchi O et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect. Immun. 2000; 68: 6883-90.
10. Goldmann O, Rohde M, Medina E. Phagocytosis of bacille Calmette-Guerin-infected necrotic macrophages induces a maturation phenotype and evokes antigen-presentation functions in dendritic cells. Immunology 2002; 107: 500-6.
11. Estevez F, Carr A, Solorzano L et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 1999; 18: 190-7.
12. Mesa C, de León J, Rigley K, Fernández LE. Very Small Size Proteoliposomes derived from Neisseria meningitidis: an effective Adjuvant for Th1 induction and Dendritic Cell activation. Vaccine 2004; 22: 3045-52.
13. Carr A, Estevez F, Mazorra Z et al. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res. 2001; 3: 219-27.
14. Carr A, Rodríguez E, Arango M et al. Immunotherapy of advanced Breast cancer with a heterophilic Ganglioside (NeuGcGM3) Cancer Vaccine. J. Clin. Oncol. 2003; 21: 1015-21.
15. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int. Immunol. 2000; 12: 1539-46.
16. Colaco CA. Towards a unified theory of immunity: dendritic cells, stress proteins and antigen capture. Cell. Mol. Biol. 1998; 44: 883-90.
17. Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev. Vaccines 2003; 3: 369-79.
18. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother 2002; 6: 293-8.
19. Almand B, Resser J, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000; 6: 1755-66.
20. Almand B, Clark J, Nikitina E et al. Increased production of immature myeloid cells in cancer patients as a mechanism of immunosuppression in cancer. J. Immunol. 2001; 166: 678-89.
21. Bronte V, Apolloni E, Cabrelle A et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96: 3838-46.
22. Dong R, Cwynarski K, Entwistle A et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003; 101: 3560-7.
23. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nature Immunol. 2004; 1: 7-10.
24. Esche C, Shurin MR, Lotze MT. The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther. 1999; 1: 72-81.
25. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15: 94-103.
26. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 1999; 50: 507-29.
27. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-4.
28. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-9.
29. Heath WR, Carbone FR. Cytotoxic T lymphocyte activation by cross-priming. Curr. Opin. Immunol. 1999; 11: 314.
30. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide or tumour lysate-pulsed dendritic cells. Nat. Med. 1998; 4: 328-32.
31. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 2000; 191: 423-34.
32. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 1993; 178: 1391-6.
33. Arnold D, Faath S, Rammensee HG, Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 1995; 182: 885-9.
34. Schild H, Arnold-Schild D, Lammert E, Rammensee HG. Stress proteins and immunity mediated by cytotoxic T lymphocytes. Curr. Opin. Immunol. 1999; 11: 109-13.
35. Singh-Jasuja H, Toes RE, Spee P et al. Cross-presentation of glycoprotein 96-associated antigens on major histocom-patibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 2000; 191: 1965-74.
36. Maurer T, Heit A, Hochrein H et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 2002; 32: 2356-64.
37. Pawelec G. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol. Immunother 2004; 53: 262-74.
38. Fayad L, Keating MJ, Reuben JM et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001; 97: 256-63.
39. Sarris AH, Kliche KO, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol. 1999; 10: 433-40.
40. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Rev. Immunol. 1998; 16: 137-61.
41. Crowley M, Inaba K, Steinman RM. Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins. J. Exp. Med. 1990; 172: 383-6.
42. Inaba K, Turley S, Yamaide F et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med. 1998; 188: 2163-73.
43. Tsuchiya Y, Igarashi M, Suzuki R, Kumagai K. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J. Immunol. 1988; 141: 699-708.
44. 2-dependent and independent immune suppressor cells by tumor-derived GM-CSF and M-CSF. J. Leukoc. Biol. 1993; 53: 86-92.
45. Gabrilovich D, Velders M, Sotomayor E, Kast W. Mechanism of immune dysfunction in cancer mediated by immature Gr-1(+) myeloid cells. J. Immunol. 2001; 166: 5398-406.
46. Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H, Tominaga T. Clinical significance of the determination of angiogenic factors [review]. Eur. J. Cancer 1996; 32A: 2513-19.
47. Ferrara N, Smyth D. The biology of vascular endothelial growth factor. Endocr. Rev. 1997; 18: 4-25.
48. Dikov M, Oyama T, Cheng P et al. Vascular endothelial growth factor effects on nuclear factor-kappa B activation in hematopoietic progenitor cells. Cancer Res. 2001; 61: 2015-21.
49. Oyama T, Ran S, Ishida T et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa β activation in hemopoietic progenitor cells. J. Immunol. 1998; 160: 1224-32.
50. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotypes antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998; 92: 1184-90.
51. Vogel C, Cobleigh MA, Tripathy D et al. First-line, single agent Herceptin (trastuzumab) in metastatic breast cancer: a preliminary report. Eur. J. Cancer 2001; 37: 25-7.
52. Riethmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 1994; 434: 1177-83.
53. Cottrez F, Hurst SD, Coffman RL, Groux H. T regulatory cells 1 inhibit a Th2-specific response in vivo. J. Immunol. 2000; 165: 4848-53.
54. Birkett A, Lyons K, Schmidt A et al. A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts. Infect. Immun. 2002; 70: 6860-70.
55. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999; 17: 2517-27.
56. Lappin MB, Campbell JD. The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy. Blood Rev. 2000; 14: 228-39.
57. Peschel C, Huber C, Aulitzky WE. Clinical applications of cytokines. Presse Med. 1994; 23: 1083-91.
58. Aebischer T, Wolfram M, Patzer SI, Ilg T, Wiese M, Overath P. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect. Immun. 2000; 68: 1328-36.
59. Finn OJ. Cancer Vaccines: between the idea and the reality. Nature 2003; 3: 630-41.
60. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumour immune escape. J. Cell Physiol. 2003; 195: 346-55.
61. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma association with disease progression. Am. J. Pathol. 1999; 154: 745-54.
62. Bacso Z, Bene L, Damjanovich L, Damjanovich S. IFN-gamma rearranges membrane topography of MHC-1 and ICAM-1 in colon carcinoma cells. Biochem. Biophys. Res. Commun. 2002; 290: 635-40.
63. Carnaud C, Lee D, Donnars O et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 1999; 163: 4647-50.
64. + T cells. Cancer Res. 2003; 63: 4095-100.
65. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumour cells. Blood 1999; 93: 1634-42.
66. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99: 2468-76.
67. Restifo NP. Not so Fas: re-evaluating the mechanisms of immune privilege and tumour escape. Nat. Med. 2000; 6: 493-5.
68. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999; 59: 3128-33.
69. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999; 163: 5211-18.
70. Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology 2002; 107: 5-9.
71. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 2000; 192: 1213-22.
72. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 2001; 193: F5-9.
73. + T Cell Mediated Suppression by Dendritic Cells. Science 2003; 299: 1033-6.
74. Sercarz EE. Driver clones and determinant spreading. J. Autoimmun. 2000; 14: 275-7.
75. Vanderlugt CL, Miller SD. Epitope spreading in immune mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2002; 2: 85-95.
76. Ribas A, Timmerman JM, Butterfieldand LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003; 24: 58-61.
77. Lally BCM, Mocellin S, Ohnmacht GA et al. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer 2001; 93: 841-7.
78. Butterfield LH, Ribas A, Dissette VB et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 2003; 9: 998-1008.
79. Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int. Immunol. 2001; 13: 625-32.
80. el-Shami K, Tirosh B, Bar-Haim E et al. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur. J. Immunol. 1999; 29: 3295-301.